Company intelligence / Profile preview

Anumana

Cambridge, Massachusetts, United Statesanumana.ai ↗

Ownership: Private
Development stage: Commercial

Overview

Anumana has received FDA clearance for its ECG-AI LEF algorithm for detecting low ejection fraction. The algorithm is currently available in the U.S. and eligible for reimbursement as of January 2025.

Therapeutic areas: Cardiovascular
Modalities: AI algorithmssoftware medical devices
Industry: Physiological Monitoring

Partnerships

Mayo ClinicJanssenNovartisPfizerAmerican College of Cardiology

Beyond the preview

Go deeper on Anumana.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anumana.

Explore the full profile